Ligelizumab for Chronic Spontaneous Urticaria

Abstract

M Maure, AM Gimenez-Arnau, G Sussman. N Engl J Med. 2019;381(14):1321–371332 To determine the efficacy of a next generation, high affinity, humanized monoclonal anti-IgE antibody in the treatment of chronic spontaneous urticaria (CSU). Patients (n = 382) were 18–75 years old with moderate to severe CSU who were not controlled with maximum medical management. The patients were randomized 2:2:2:1:1:1 to receive one of the following subcutaneous regimens: 240 mg of ligelizumab every four weeks, 72 mg of ligelizumab every four weeks, 24 mg of ligelizumab every four weeks, 300 mg of omalizumab every four weeks, placebo every four weeks, or a single 120 mg dose of ligelizumab at week zero followed by placebo …